BioCryst Pharmaceuticals Aktie - Fundamentalanalyse - Dividendenrendite KGV

BioCryst Pharmaceuticals (ISIN: US09058V1035, WKN: 896047) Kursdatum: 22.06.2018 Kurs: 5,590 USD
Beschreibung Daten
Symbol BCRX
Marktkapitalisierung 472.081.088,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet www.biocryst.com
Letztes Bilanz Update 12.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 22.06.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-11,38 -11,47 0,00% -36,95 0,55 -7,17 18,74 479,76

Firmenbeschreibung

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.biocryst.com